https://www.high-endrolex.com/10

eKonferencije.com: Anti-VEGF therapy – last solution for residual diabetic macular edema

Anti-VEGF therapy – last solution for residual diabetic macular edema

1. Vladislav Džinić, Serbia

ANTI-VEGF THERAPY – LAST SOLUTION FOR RESIDUAL DIABETIC MACULAR EDEMA Vladislav Dzinic, Miroslav Dzinic PURPOSE: to investigate the effects of intravitreal anti-VEFG (bevacizumab) application in patients with diabetic retinopathy and clinically significant residual macular edema, after laser photocoagulation treatment. METHODS: during 24 months period 26 patients (28 eyes) were followed. Mean age was 67 ± 10, 14 male and 12 female. All patients received laser photocoagulation therapy either pan retinal or macular (focal or grid) photocoagulation, depending on the severity of retinopathy, before intravitreal application of anti-VEGF. After photocoagulation FA was conducted and further laser treatment was not indicated. Visual acuity (VA) testing (Snellen chart), biomicrosopy, ophthalmoscopy, IOP and SD-OCT were conducted at baseline and follow up visits. All patients received intravitreal injection 1,25mg (0,05ml) of bevacizumab, during initial treatment and retreatment. The average number of injection per patient was 2.15. All patients used local non steroid antinflamatory therapy (NSAID) 4-6 weeks after injection. Follow up visits were conducted at the first and 7th day after injection and every 4-6 weeks after. Last follow up visit was 18 months after injection. RESULTS: Mean VA after laser photocoagulation and before treatment was 0.2 ± 0.2 and average macular thickness 430±103µm. After 6 months average macular thickness was 392±109µm. At the last follow up average VA was 0.34 ± 0.2 and macular thickness 377±82µm. Improvement was achieved in 17 eyes (60%), stabilization in 7 eyes (25%) and 4 eyes (15%) worsen. CONCLUSION: According to our study intravitreal application of bevacizumab have beneficial effects in patients with residual diabetic macular edema, despite small average number of injections. After complete laser photocoagulation anti-VEGF seems to be promising treatment option for improvement and stabilization in VA and macular thickness (p

Ključne reči :

Tematska oblast: medical retina

Uvodni rad: Da

Datum: 06.04.2012.

Br. otvaranja: 598

II Kongres oftalmologa BiH


Ostali radovi sa konferencije


Pretraži radove

https://www.high-endrolex.com/10